Arca
Skip to content
Tools
Tools

Polypeptides

Macromolecule in Homo sapiens that 6 drugs act on.

  • Drugs that act on it: 6
  • Approved: 5
  • In phases 1 to 3: 1
  • Sponsors: 6

Who is on it, and how far along

Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide 4
  • Other 2

Approved5

  • Pancrelipase
  • Chymotrypsin
  • Cerliponase alfa
  • Protease (pancrelipase)
  • Chymopapain

Phase 31

  • Liprotamase

Phase 20

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      • Aimmune Nestlé Health Science US R&D, LLC117%
      • Healthgen Biotechnology Corp.117%

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 4 of 6 act as: Polypeptides proteolytic enzyme; the rest name their own mechanism.
      PancrelipaseApprovedOrganonProtein or peptideHydrolytic enzymePolypeptides hydrolytic enzyme15
      ChymotrypsinApprovedHealthgen Biotechnology Corp.OtherProteolytic enzyme10
      Cerliponase alfaApprovedBioMarin PharmaceuticalProtein or peptideProteolytic enzyme4
      Protease (pancrelipase)ApprovedAimmune Nestlé Health Science US R&D, LLCProtein or peptideHydrolytic enzymePolypeptides hydrolytic enzyme3
      ChymopapainApprovedDiscure MedicalOtherProteolytic enzyme0
      LiprotamasePhase 3Anthera PharmaceuticalsProtein or peptideProteolytic enzyme0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 20 in all, from ClinicalTrials.gov.
      Efficacy and Safety of OsrhCT Before Upper Endoscopy on Improving Visualization of the Gastric Mucosa.ChymotrypsinPhase 2Not yet recruitingHealthgen Biotechnology Corp.Oct 26, 2026
      Pancreatin Added to Standard Antihyperglycemic Therapy in Patients With Type 2 DiabetesPancrelipasePhase 4RecruitingSilesian Centre for Heart DiseasesOct 1, 2026
      Comparison Of Acetaminophen, NSAIDs, And Trypsin-Chymotrypsin Plus Acetaminophen For Post-Endodontic Pain After Single-Visit Root Canal TreatmentChymotrypsinEarly phase 1RecruitingDow University of Health SciencesAug 12, 2026
      A Study on the Efficacy of Different Doses of Oryz-Aspergillus Enzyme And Pancreatin Tablet in Treating Pancreatic Exocrine Insufficiency After Gastrointestinal SurgeryPancrelipaseNot applicableNot yet recruitingTianjin Medical University Cancer Institute and HospitalAug 7, 2026
      Efficay of Physical Activity Program in PCOS Females With Fatty Pancrease and Thyroid HypofunctionPancrelipaseNot applicableRecruitingCairo UniversityMay 15, 2026
      A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.Pancrelipase, Protease (pancrelipase)Phase 2RecruitingAimmune Nestlé Health Science US R&D, LLCApr 30, 2026
      A Prospective Non-randomized Controlled Interventional Study on the Effect of Shouhui Tongbian Capsules Combined With Pancreatin Enteric-coated Capsules on Pancreatic Exocrine Function in Patients After Curative Resection for Pancreatic CancerPancrelipasePhase 4Not yet recruitingShanghai General Hospital, Shanghai Jiao Tong University School of MedicineApr 29, 2026
      Phase 2 Study to Assess the Safety and Efficacy of ANG003Pancrelipase, Protease (pancrelipase)Phase 2RecruitingAnagram Therapeutics, Inc.Mar 4, 2026
      A Study on the Changes of Glucose Metabolism and Exocrine Function in Patients With Chronic PancreatitisPancrelipase, Protease (pancrelipase)Early phase 1RecruitingShanghai Changzheng HospitalJan 2, 2026
      Endotherapy and/or Extracorporeal Shockwave Lithotripsy for Painless Chronic PancreatitisPancrelipaseNot applicableRecruitingChanghai HospitalJul 20, 2025
      Phase II Clinical Trial of KJ101in the Treatment of Deep II Degree BurnsChymotrypsinPhase 2RecruitingShanghai Bao Pharmaceuticals Co., Ltd.Jun 17, 2025
      Efficacy and Safety of OsrhCT and Dimethicone Emulsion Before Upper Endoscopy on Visualization of the Gastric Mucosa.ChymotrypsinPhase 2Active, not recruitingHealthgen Biotechnology Corp.Dec 9, 2024
      Comparison of Clinical Efficacy of Submucosal Dexamethasone and Oral Trypsin-chymotrypsin for Reduction of Postoperative Sequelae After Lower Third Molar SurgeryChymotrypsinNot applicableRecruitingB.P. Koirala Institute of Health SciencesDec 3, 2024
      Premedication on Post-endodontic PainChymotrypsinPhase 3RecruitingGulf Medical UniversityNov 4, 2024
      Imaging Biomarkers of Pancreatic Function and DiseaseChymotrypsinPhase 4Enrolling by invitationChildren's Hospital Medical Center, CincinnatiDec 21, 2022
      Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2Cerliponase alfaPhase 1 / Phase 2Active, not recruitingDavid L Rogers, MDDec 10, 2021
      Natural History and Longitudinal Clinical Assessments in NCL / Batten Disease, the International DEM-CHILD DatabaseCerliponase alfa—RecruitingUniversitätsklinikum Hamburg-EppendorfNov 3, 2020
      An Observational Study on the Natural Course of Chronic PancreatitisChymotrypsin—Active, not recruitingChanghai HospitalOct 5, 2020
      Cerliponase Alfa Observational Study in the USCerliponase alfa—Active, not recruitingBioMarin PharmaceuticalJul 20, 2020
      Examining Developmental Outcomes of Children Diagnosed With CLN2 DiseaseCerliponase alfa—Enrolling by invitationJessica ScherrMar 5, 2019

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364181, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.